Healthymagination: GE Healthcare

Reinvest current net income into interest accounts for future variable health care costs for years to come

This charge is also another revenue stream for the hospital and contributes to the ROI of the equipment. GE, which is the manufacturer of the equipment, indicates that the equipment has a viable life span of up to 15 years, but the warranty only covers the first 6 years of use (Price, 2011). The above figures are a clear indication that the MRI equipment can provide the hospital with an adequate return on investment. These figures, the machine’s lifespan, and the growing demand for MRI scans serve to justify the purchase of the equipment. Other factors that enhance the returns from the equipment include:

As Executive Director, I will provide staff leadership for Better Health Association. Our goal for the company is to improve the well-being of individuals. Audiences of all ages will be able to take part in learning about living a healthy lifestyle and developing the skills needed to make healthy choices to prevent diseases and ameliorate conditions for those already afflicted with illnesses. Over the course of the next year, It is my responsibility to develop and lead the staff, management structure, dedicated to achieving the mission for Better Health Care Organization. I plan to make significant changes to our organization, to help guide individuals in Central Ohio, to living a better and healthier lifestyle. My goal is to empower the staff with the training needed to meet our company’s standards.

Poor nutrition in the United States is indeed a scary factor that continues to lead our citizens to chronic healthcare conditions. The article notes “Health People 2020 states the most affected are non-White, Hispanic adult populations are disproportionately affected by obesity” (Kaiser Foundation Hospital, 2014, p. 6)

The next factor to consider is competitive position and healthcare firms can substantially ensure higher quality of care when pricing there products and services at an increased level. Aside from pricing, cost is another major aspect since it can drastically affect a company’s competitive position. A hard investment would involve a MRI device that insurance companies or healthcare organizations could reimburse the office at a higher rate for providing the patients of improved cost-efficient results. As a result, such benefits accrue primarily from savings in drug expenditures, improved utilization of radiology tests, better capture of charges, and decreased billing errors, (Wang et al., 2003). Physician providers are always in competition with the latest and greatest technology, EMR system, and most effective medication for patients.

As Executive Director, I will provide staff leadership for Better Health Association. Our goal for the company is to improve the well-being of individuals. Audiences of all ages will be able to take part in learning about living a healthy lifestyle and developing the skills needed to make healthy choices to prevent diseases and ameliorate conditions for those already afflicted with illnesses. Over the course of the following year, it is my responsibility to develop and lead the staff, management structure, dedicated to achieving the mission for Better Health Care Organization. I plan to make significant changes to our organization, to help guide individuals in Central Ohio, to living a better and healthier lifestyle. My goal is to empower the staff with the training needed to meet our company’s standards.

21. What proportion of the drugs tested on human subjects are eventually approved by the FDA?

While GEHS is the current market leader there is tumultuous change happening in the market with the aging

3. No new drugs are to be available in the market for this indication in the next 5 years so it makes the product very lucrative.

In 2010, Healthy People 2020 was started by the Department of Human Health Services. Health programs and research topics were instituted to help Americans live healthier and longer lives (CDC, 2014). The 42 topics presented are all very important in maintaining the goals set by Healthy People 2020. If these programs were to be cut or budget restraints imposed on them, the impact would be felt by all Americans. There would be more unhealthy people, preventable chronic diseases would be more prevalent, and education and health associated programs would be

GE Healthcare India, one of the main stakeholders in this issue, sold 18,255 ultrasound scanners in India from 2002 to 2006 and had whopping sales of $77 million in 2006. As a result of the rising criticism of ultrasound machines sold by their company, they have faced legal issues, intense government scrutiny and pushback from activists for having aggressive sales tactics. Completely banning ultrasounds would have an adverse effect on their company and its sales.

Currently Brazil is the largest market for products and services for health in Latin America, with annual expenditures of approximately U.S. $ 107 billion. This figure is comparatively higher than other countries to which Genicon can expand its operations. In addition, the health expenditure showed an average annual growth of 15.6%, while GDP growth has averaged 2.4% per year for Brazil which implies a sustained growth in demand for endoscopy instruments. The figures for the healthcare market in Brazil, shows that the profile of the healthcare market of the country is comparable to the healthcare market in the United States around 1965, in terms of growth rate and a proportion of total spending. Thus, Genicon can reasonably expect to grow with the rising wave of the healthcare market.

Cost: This would be the most difficult to measure, and since GE would have no control in setting price for service, it is unclear if there would even be an impact in this. That being said, however, if the Omega device grants the ability of midwives to perform diagnostics that would otherwise require a hospital, we can say the cost savings of using a midwife vs. going to a hospital were related to the use of the Omega system.

After analyzing the results from the previous quarter, it was determined that the prices set for each segment were not sufficient. Product sales priority were also not properly adjusted. With the R&D investments, sales priorities needed to be changed for the main focus to become the most profitable market segments. Prices were not competitive which in turned decreased revenue, market share, and profitability. To become more competitive we altered the prices in each market segment. The Workhorse product was the first to change, the price was lowered to $2500 in an attempt to increase sales; at this price Team 4 was still making a profit on this product, as well as making the price much more competitive. The Workhorse sales priority was also lowered to 3rd in Americas and 4th in APAC and EMEA. This product was not selling as well as we had hoped, and was no longer as profitable as it once was which led to this decision. Next, the Innovator product’s price was adjusted; this involved a price increase to $4100. This price was adjusted to include the new

One factor that must be considered is that the drug had not yet been approved by the FDA, but was in phase III trials. Historical data shows that 65% of drugs in this phase eventually get approved for sale to the market. It was felt that approval of the drug would occur late in 1998.